- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | LeonaBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | LeonaBio, Inc.: LeonaBio to Participate in Upcoming Medical and Industry Meetings in June | 3 | GlobeNewswire (USA) | ||
| 27.05. | Piper Sandler initiates LeonaBio stock with overweight rating | 2 | Investing.com | ||
| 27.05. | Piper Sandler startet Coverage für LeonaBio mit "Overweight" und hohem Kursziel | 3 | Investing.com Deutsch | ||
| LEONABIO Aktie jetzt für 0€ handeln | |||||
| 07.05. | LeonaBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | LeonaBio, Inc.: LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. | 3 | GlobeNewswire (USA) | ||
| 23.04. | LeonaBio, Inc.: LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer | 1 | GlobeNewswire (USA) | ||
| 21.04. | LeonaBio, Inc.: Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data | 1 | GlobeNewswire (USA) | ||
| 07.04. | Cantor Fitzgerald reiterates Overweight on LeonaBio stock | 2 | Investing.com | ||
| 06.04. | Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook | 3 | Investing.com | ||
| 01.04. | LeonaBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 27.03. | LeonaBio GAAP EPS of -$24.70 | 12 | Seeking Alpha | ||
| 27.03. | Athira Pharma GAAP EPS of -$24.70 | 2 | Seeking Alpha | ||
| 26.03. | LeonaBio, Inc.: LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update | 369 | GlobeNewswire (Europe) | Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer... ► Artikel lesen | |
| 19.03. | LeonaBio: Aktionäre genehmigen neuen Eigenkapital-Plan und Aufstockung des genehmigten Kapitals | 2 | Investing.com Deutsch | ||
| 19.03. | LeonaBio, Inc. - 8-K, Current Report | 10 | SEC Filings | ||
| 18.03. | LeonaBio-Aktie: +167% nach NBC-Tipp | 473 | sharedeals.de | Die deutschsprachige Biotech-Szene rund um den No Brainer Club und Chefanalyst Maximilian Ruth hat erneut geliefert. Während die breite Masse erst jetzt auf die Aktie von LeonaBio aufmerksam wird, waren... ► Artikel lesen | |
| 18.02. | Mizuho upgrades LeonaBio stock rating on breast cancer drug potential | 14 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,906 | +1,41 % | Evotec-Aktie mit -91% - ist das die letzte Chance? | Die Evotec-Aktie hat seit ihrem Allzeithoch rund -91% an Wert verloren und zählt damit zu den größten Verlierern der vergangenen Jahre. Nach dem massiven Abverkauf bewegt sich der Kurs nun in einer... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| INTELLIA THERAPEUTICS | 14,120 | -3,42 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 84,15 | +4,08 % | Biotech Hoffnung erhält Dämpfer: Abivax Aktie stürzt nach Höhenflug ab Krebs Signale belasten Investmentstory | Die Abivax Aktie hat nach ihrem starken Höhenflug einen herben Rückschlag erlitten. Auslöser sind neue Sicherheitsfragen rund um den Hoffnungsträger Obefazimod. Obwohl der Wirkstoff in klinischen Studien... ► Artikel lesen | |
| IBIO | 1,443 | -1,30 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| IMMUNITYBIO | 7,590 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,200 | -1,97 % | Immatics N.V. - S-8, Securities to be offered to employees in employee benefit plans | ||
| LAKEFRONT BIOTHERAPEUTICS | 25,140 | -2,18 % | Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer | ||
| CELLECTAR BIOSCIENCES | 2,520 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| MANNKIND | 3,577 | 0,00 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,067 | -3,18 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| IMMUNIC | 13,115 | -1,83 % | EQS-News: Immunic AG: Immunic to Participate in Investor, Industry and Scientific Conferences in June | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor, Industry and Scientific Conferences in June
10.06.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,740 | +0,54 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen |
LEONABIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,005 (+0,05 %) liegt der Kurs bei 9,405 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEONABIO INC finden Sie auf Wallstreet Online.